Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients

Figure 2

Overall survival: adjusted for age, tumor grade, histology and platinum response status. Cox proportional hazards model when impact of tumor histology, grade, patients’ age and platinum response status were adjusted showed that death risk was 3.3 times higher in patients who experienced only chemotherapy delays compared with patients who experienced no chemotherapy delays or platinum dose reduction (HR = 3.3, 95% Cl: 1.2 – 8.5, p = 0.016) and also showed that death risk was 2.3 times higher in patients who experienced only chemotherapy delays compared with patients who experienced both chemotherapy delays and platinum dose reduction (HR = 2.3, 95% Cl: 1.1 – 4.8, p = 0.021).

Back to article page